Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)

Shigenori E Nagai¹, Masaya Hattori², Tetsuhiro Yoshinami³, Hiroko Masuda⁴, Takuho Okamura⁵, Kenichi Watanabe⁶, Takahiro Nakayama⁷, Michiko Tsuneizumi⁸, Daisuke Takabatake⁹, Michiko Harao¹⁰, Hiroshi Yoshino¹¹, Natsuko Mori¹², Hiroyuki Yasojima¹³, Chiya Oshiro¹⁴, Madoka Iwase¹⁵, Miki Yamaguchi¹⁶, Takafumi Sangai¹⁷, Shinsuke Sasada¹⁸, Takanori Ishida¹⁹, Manabu Futamura²⁰, Yasuaki Muramatsu²¹, Nobuyoshi Kosaka²¹, Norikazu Masuda²²

Affiliations

¹ Division of Breast Oncology, Saitama Prefectural Cancer Center, Saitama, Japan.
² Department of Breast Oncology, Aichi Cancer Center, Nagoya, Japan.
³ Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
⁴ Department of Breast Surgical Oncology, School of Medicine, Showa University, Tokyo, Japan.
⁵ Department of Breast Oncology, Tokai University School of Medicine, Tokyo, Japan.
⁶ Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
⁷ Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan.
⁸ Department of Breast Surgery, Shizuoka General Hospital, Shizuoka, Japan.
⁹ Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
¹⁰ Department of Breast Oncology, Jichi Medical University, Shimotsuke, Japan.
¹¹ Breast and Endocrinological Surgery, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
¹² Department of Breast Surgery, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
¹³ Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
¹⁴ Department of Breast Surgery, Kaizuka City Hospital, Osaka, Japan.
¹⁵ Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Japan.
¹⁶ Department of Breast Surgery, JCHO Kurume General Hospital, Kurume, Japan.
¹⁷ Department of Breast and Thyroid Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
¹⁸ Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
¹⁹ Division of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
²⁰ Department of Breast Surgery, Gifu University Hospital, Gifu, Japan.
²¹ Oncology Medical Affairs, Pfizer Japan Inc, Tokyo, Japan.
²² Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507, Japan. nmasuda@alpha.ocn.ne.jp.

PMID: 41591707
DOI: 10.1007/s12282-025-01787-3

Published Erratum

Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)

Shigenori E Nagai et al. Breast Cancer. 2026.

. 2026 Jan 27.

doi: 10.1007/s12282-025-01787-3. Online ahead of print.

Authors

Affiliations

¹ Division of Breast Oncology, Saitama Prefectural Cancer Center, Saitama, Japan.
² Department of Breast Oncology, Aichi Cancer Center, Nagoya, Japan.
³ Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
⁴ Department of Breast Surgical Oncology, School of Medicine, Showa University, Tokyo, Japan.
⁵ Department of Breast Oncology, Tokai University School of Medicine, Tokyo, Japan.
⁶ Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
⁷ Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan.
⁸ Department of Breast Surgery, Shizuoka General Hospital, Shizuoka, Japan.
⁹ Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
¹⁰ Department of Breast Oncology, Jichi Medical University, Shimotsuke, Japan.
¹¹ Breast and Endocrinological Surgery, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
¹² Department of Breast Surgery, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
¹³ Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
¹⁴ Department of Breast Surgery, Kaizuka City Hospital, Osaka, Japan.
¹⁵ Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Japan.
¹⁶ Department of Breast Surgery, JCHO Kurume General Hospital, Kurume, Japan.
¹⁷ Department of Breast and Thyroid Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
¹⁸ Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
¹⁹ Division of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
²⁰ Department of Breast Surgery, Gifu University Hospital, Gifu, Japan.
²¹ Oncology Medical Affairs, Pfizer Japan Inc, Tokyo, Japan.
²² Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507, Japan. nmasuda@alpha.ocn.ne.jp.

PMID: 41591707
DOI: 10.1007/s12282-025-01787-3

No abstract available

PubMed Disclaimer

Erratum for

Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).
Nagai SE, Hattori M, Yoshinami T, Masuda H, Okamura T, Watanabe K, Nakayama T, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Sasada S, Ishida T, Futamura M, Muramatsu Y, Kosaka N, Masuda N. Nagai SE, et al. Breast Cancer. 2025 Jul;32(4):705-715. doi: 10.1007/s12282-025-01689-4. Epub 2025 Apr 5. Breast Cancer. 2025. PMID: 40186791 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Springer
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)

Affiliations

Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study)

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous